EVO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Evotec SE does not present a strong buy opportunity for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock's technical indicators are mixed, with bearish moving averages and neutral RSI, while its financial performance shows declining revenue and negative gross margins. Analyst ratings are mixed with some optimism but also recent price target reductions. Without strong positive catalysts or trading signals, holding off on this investment is recommended.
The MACD is positive and expanding, indicating some bullish momentum. However, the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the RSI is neutral at 61.853. The stock is trading near resistance levels (R1: 2.564), suggesting limited upside in the short term.
Appointment of Dr. Ashiq H. Khan as Chief Commercial Officer, which may enhance customer value and drive sustainable growth.
Declining revenue (-5.70% YoY) and negative gross margin (-100.40% YoY) in the latest quarter. Analysts have lowered price targets recently, and the stock trend suggests a potential decline in the short term.
In Q3 2025, revenue dropped by -5.70% YoY to $191.55M. Net income improved slightly but remains negative at -$50.36M (+15.65% YoY). EPS increased to -0.28 (+12.00% YoY), and gross margin dropped significantly to -0.04 (-100.40% YoY).
Analyst ratings are mixed. Deutsche Bank lowered its price target to EUR 4.50 and maintained a Hold rating. Berenberg initiated coverage with a Buy rating and a EUR 10 price target, citing the company's leading position in drug discovery and favorable market trends.
